[Composite phytoadaptogens in oncology and gerontology].

The article describes results of research devoted to Phytomix-40, a mixture of plant adaptogens. It focuses on immunobiological criteria for its formulation, chemical composition and manufacture procedures, biological standartization tests, in vitro and in vivo preclinical studies, clinical trials in patients with non-malignant tumours (benign prostatic hyperplasia), precancer (oral leukoplakia), advanced cancer (malignant gastric cancer), and age-related neurodegenerative disease (parkinsonism). Prospects for the development of other plant preparations for non-toxic prevention and treatment of cancer and prolongation of life span of the affected subjects are discussed.

[Phosphogliv: mechanism of therapeutic action and clinical efficacy]. / Fosfogliv: mekhanizm deistviia i éffektivnost' primeneniia v klinike.

The review summarizes the results of long term study (from design to clinical trial) of a new hepatoprotective drug Phosphogliv. Some theoretical ground for its creation has been considered with special emphasis on its ingredient properties: soy bean phosphatidylcholine and glycyrrhizinic acid from licorice roots. Experimental and clinical data concerning polyene phosphatidylcholine repairing action on cell membranes as well as antiviral and immunomodulating effects of glycyrrhizinic acid are presented. Their selected combination in Phosphogliv provided its high efficiency in rat hepatitis models. After standard toxicology tests it was allowed to carry out the clinical trials of this preparation in the treatment of liver diseases patients--mainly with acute and chronic viral hepatitis B, C, A and mixed hepatitis B + C (total 203 patients). The inclusion of Phosphogliv into therapy coarse accelerated disappearance of intoxication symptoms and decrease of serum aminotransferase and other hepatic markers. The effect was more pronounced for intravenous drug form.

[RNA transduction by phage MS2 noninfectious virions]. / RNK-transduktsiia neinfektsionnymi virionami faga MS2.

Two fragments (1.9 and 1.8 kb) including, respectively, "structural" genes (A, B, and lysis polypeptide) and "replicase" gene, were obtained by reverse transcription PCR on the template of bacteriophage MS2 genome RNA. The fragments contained a common sequence which allowed the assembly of the entire functional genome sDNA. 1.8 kb fragment was subjected to two independent modifications: 1) so that the replicase gene could be replaced by other sequences no more than 1.5 kb in size and 2) it was inserted (on an artifician Tn-like structure) into E. coli chromosome. A system for replication of MS2-like corpuscles was thus created, containing a "shortened" genome and having extra genes. For extra genes, aminoglycoside-3'-phosphotransferase (kanamycin resistance) or a sequence of antiviral genetic program directed against hepatitis C virus were used.

[Modern approaches to pharmacotherapy of diabetes mellitus type II]. / Sovremennye podkhody k farmakoterapii sakharnogo diabeta II tipa.

The pharmacological approaches to the treatment of type 2 diabetes mellitus were reviewed. Special attention was paid to the new therapeutic agents that are able to decrease plasma glucose levels. The possible mechanisms of the hypoglycemic effects are discussed. Briefly, repaginide, nateglinede and alpha-glucosidase inhibitors prevent postprandial hypoclycemia while thiazaolidinediones improve the sensitivity to insulin and vanadium compounds act as an insulin action enhancer.

[New domestic phospholipid preparation "Fosfogliv" as an effective treatment for patients with acute viral hepatitis]. / Novyi otochestvennyi fosfolipidnyi preparat "Fosfogliv" kak effektivnoe sredstvo pri lechenii bol'nykh s ostrymi virusnymi gepatitami.

Patients with acute viral hepatitis B, A and mixed hepatitis B + C were treated in two independent clinics with phosphogliv--a new hepatoprotective drug based on polyunsaturated phosphatidylcholine and glycyrrhizic acid salt. Phosphogliv removed some symptoms of intoxication (nausea, weakness, jaundice, etc.) quicker than basic therapy. Among biochemical hepatitis markers, serum bilirubin level was most responsive to phosphogliv. Standard therapy decreases bilirubin by 30% on the average for 5 days, phosphogliv reduces bilirubin for one more week to half those values observed in control patients. At that point low aminotransferase activities were seen in phosphogliv treated patients. No side effects were seen. The new hepatoprotector phosphogliv which repairs biomembranes represents drugs of new generation compared to phospholipid drug essential.

[Hepatoprotective action of phosphogliv in surgery of patients with chronic calculous cholecystitis]. / Gepatoprotektornoe deistvie fosfogliva u bol'nykh, operirovannykh po povodu khronicheskogo kal'kuleznogo kholetsistita.

32 patients with chronic calculous cholecystitis were treated by a new preparation. Phosphogliv (on the base of polyunsaturated phospholipids)--5 days before planned surgery and 5 days after. The increase of alanine and asparagine aminotransferases activities and of bilirubin concentration (2-2.5 fold) was observed in all the patients, cirespective of the drug treatment. However, the essential difference between treated and untreated patients was revealed in the course of post-operative period. In the control group asparagine aminotransferase activity and bilirubin level remained high, and alanine aminotransferases activity even more increased. In contrast, both two aminotransferases activities and bilirubin level fell substantially in Phosphogliv group, that may show more active liver regeneration after surgery. Besides, in this group operation did not result even in short-time changes of plasma protein fractions ratios--opposite to control. It may testify on some protective action of Phosphogliv on liver protein-synthesis system. The observed action of new phospholipid preparation Phosphogliv, together with the absence of side effects, allows to recommend it as an adjuvant in the surgery of patients with chronic calculous cholecystitis. Besides, the above results broaden usage field of polyunsaturated phosphatidylcholine as cell membranes repair agent: it appears to be effective not only for liver diseases treatment, but also for soonest overcome of post-surgery liver changes.

[Comparative study of the effects of essentiale and the novel Russian hepatoprotective agent "phospholiv" in a model of acute hepatitis in rats]. / Sravnitel'noe issledovanie deistviia éssentsiale i novogo otechestvennogo gepatoprotektora "fosfoliv" na modeli ostrogo gepatita u krys.

Curative effect of new preparation "Phospholiv", elaborated in Institute of Biomedical Chemistry, in acute CCl4 induced rat hepatit model was studied. The preparation consists of polyunsaturated phosphatidylcholine and glycyrrhizinic acid salt. Recovery of damaged biosynthesis of albumin and total cell liver RNA--by incorporation of C14-leucine and C14-orotic acid--were observed after 3 days Phospholiv administration, that showed on reparation of damaged protein-synthesis system. Label incorporation into liver fraction > 80S--that was decreased under CCl4 influence--was also restored after Phospholiv treatment, that may testify on its regenerative effect on wholeness of subcellular hepatocytes structures. Substantial decrease of morphologic damages of liver tissue was demonstrated as well. Other phospholipid preparation--known hepatoprotector Essentiale--gave some positive effects too, but Phospholiv influence on biochemical and morphological liver features were 1.5-2 fold as compared with that of Essentiale. Results show on efficiency of polyunsaturated phospholipids in the treatment of acute hepatit in rats--as a result of influence on hepatocytes cell membrane--and on preferential effect of new hepatoprotector Phospholiv.

[Use of a novel hepato-protective preparation "phospholiv" for inhibition of development of chronic hepatitis in rats]. / Tormozhenie s pomoshch'iu novogo gepato-protektornogo preparata "fosfoliv" razvitiia khronicheskogo gepatita u krys.

Protective influence of a new phospholipid preparation "Phospholiv" was studied using a model of chronic hepatitis. Animals were treated 45 days intraperitoneay with CCl4 with parallel intragastral administration of Phospholiv or--(for comparison)--the of other phospholipid hepatoprotector, Essential. Morphologic changes of liver, as well as protein and RNA biosynthesis were evaluated in the end of experiment--by means of measuring C14-leucine and C14-orotic acid incorporation into hepatocyte subcellular fractions. Both phospholipid preparations attenuated dystrophic liver changes, Phospholiv effect being more pronounced. They both prevented CCl4 induced inhibition of label incorporation into subcellular fraction proteins, but only Phospholiv, promoted the maintaining normal level of radioactivity incorporation into cytosol proteins and hepatocyte RNA. The results, confirming certain protective effect of Essential, show more pronounced hepatoprotective action of the new preparation Phospholiv (developed on the basis of polyunsaturated phosphatidylcholine and glycyrrhizinic acid salt). Data show also on possible fit hepatitis treatment.

[Basic trends in the development and realization of state scientific and technical programs in the field of preventive medicine]. / Osnovnye napravleniia razrabotki i realizatsii gosudarstvennykh nauchno-tekhnicheskikh programm v oblasti profilakticheskoi meditsiny.

Reviews the state research and technological programs on priority trends in medical science. The programs are aimed at improving the nation's health. The emphasis in these programs is laid upon prophylactic medicine and the sociohygienic approach, underlying the health status of children and adults in the country.

[Experimental validation of the use of betamecil in ophthalmology]. / Eksperiemntal'noe obosnovanie primeneniia betametsila v oftal'mologii.

Wound-healing activity of 2% betamicil ointment in comparison with the traditional stimulants of corneal repair regeneration (methyluracyl and solcoseril) was studied in experiments. The rate of epithelialization of a standard trephination wound in rabbit cornea (28 animals), mitotic activity of the anterior corneal epithelium, and strength of the regenerated tissue were assessed after use of different stimulants and in control. A maximal positive effect of local betamicil (2% ointment) was observed: the wounds epithelialized 57% sooner than in control, but there was no reliable difference from solcoseril; the regenerate of linear corneal wound was 1.5 times stronger. Use of this ointment in ophthalmology is validated.

[The development and realization of government scientific and technical programs in the field of nutritional rationalization for the population in ecologically unfavorable regions of Russia]. / Razrabotka i realizatsiia gosudarstvennykh nauchno-tekhnicheskikh programm v oblasti ratsionalizatsii pitaniia naseleniia ékologicheskoi neblagopriiatnykh regionov Rossii.

New approaches in development of research state politics in field concerning of dietary intake improving for population living in ecological unfavorable regions are suggested. Scientific analysis of effectivity of state funded research project in first priority subjects of medical sciences carried out by Ministry of science and research politics of Russia has been fulfilled. Concrete results of research program realizations in health care system including dietary intake rationalization, environmental improving and elaboration of new medicines and preventive means.

[Implementation of international scientific and technological projects in the study of consequences of the Chernobyl AES accident]. / Realizatsiia mezhdunarodnykh nauchno-tekhnicheskikh proektov v oblasti izucheniia posledstvii avarii na Chernobyl'skoi AES.

The paper discusses the approaches and scientific and organizational principles used in the development of some International research projects in the study of consequences of the Chernobyl accident, which are under way by Russia's Ministry of Science and Engineering Policy. Special attention is given to sociomedical aspects and the possibilities of defining an individual medical policy while working with the liquidators and the members of their families.